Eden Biodesign has completed a successful second audit by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), European Medicines Agency (EMEA) to manufacture Investigational Medicinal Products (IMPs) at its facility in Liverpool, UK. The three-day MHRA inspection took place in March 2009 and demonstrates that the company’s processes, facilities and quality systems meet cGMP standards, with no critical or major deficiencies found by the inspector. “I am delighted that our wor...